Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| No statute on record | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REILLY, SOPHIA JANE | 2 | 59.3% | +51.1% |
| VARADARAJ, ARCHANA | 1 | 100.0% | +0.0% |
| WESTERBERG, NISSA M | 1 | 23.4% | +36.9% |
| LEE, CHIHYI NMN | 1 | 32.5% | +62.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801057 | PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE AND SODIUM BICARBONATE HAVING EXCELLENT RELEASE PROPERTIES | WESTERBERG, NISSA M | 79d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801057 | PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE AND SODIUM BICARBONATE HAVING EXCELLENT RELEASE PROPERTIES | WESTERBERG, NISSA M | 79d overdue |
| 17995947 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | REILLY, SOPHIA JANE | 5d overdue |
| 17614967 | 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | LEE, CHIHYI NMN | 4d overdue |
| 18287743 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | REILLY, SOPHIA JANE | 47d |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1658 | 1 |
| 1618 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287743 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | REILLY, SOPHIA JANE | 1627 | §103 | Non-Final OA | 47d | Pending | Oct 20, 2023 |
| 18010399 | INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE | VARADARAJ, ARCHANA | 1658 | Other | Non-Final OA | 33d | Pending | Dec 14, 2022 |
| 17995947 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | REILLY, SOPHIA JANE | 1627 | Other | Non-Final OA | 5d overdue | Pending | Oct 11, 2022 |
| 17801057 | PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE AND SODIUM BICARBONATE HAVING EXCELLENT RELEASE PROPERTIES | WESTERBERG, NISSA M | 1618 | Other | Final Rejection | 79d overdue | Pending | Aug 19, 2022 |
| 17614967 | 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | LEE, CHIHYI NMN | 1628 | §103 | Non-Final OA | 4d overdue | Pending | Nov 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial